Search results
Showing 16 to 30 of 365 results for heart failure
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices
Awaiting development [GID-TA10393] Expected publication date: TBC
This indicator covers the percentage of patients with a diagnosis of heart failure after (start date) which has been confirmed by an echocardiogram or by specialist assessment between 3 months before or 3 months after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM171
This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with an ACE-I or ARB. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM172
This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with a beta-blocker licensed for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM173
ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)
Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.
This indicator covers the percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional capacity (using the New York Heart Association classification) and a review of medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM174
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over with heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM238
NICE is unable to make a recommendation on vericiguat (Verquvo) for treating chronic heart failure with reduced ejection fraction in adults because Bayer did not provide an evidence submission.
Show all sections
Sections for TA731
This indicator covers admission rates due to heart failure in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG61
This indicator covers the percentage of patients with heart failure diagnosed within the preceding 15 months with a record of an offer of referral for an exercise-based rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM48
Heart failure: mortality within 12 months of admission (IND8)
This indicator covers all-cause mortality within 12 months following a first emergency admission to hospital for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG11
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults
In development [GID-IPG10411] Expected publication date: 06 August 2025
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.